Home > Boards > US Listed > Biotechs >

Anavex Life Sciences Corp (AVXL)

AVXL RSS Feed
Add AVXL Price Alert      Hide Sticky   Hide Intro
Moderator: Steady_T, bennyboy1, kund, grich1, rayovacAAA, boi568
Search This Board: 
Last Post: 11/26/2020 1:33:32 PM - Followers: 844 - Board type: Free - Posts Today: 60

Anavex Life Sciences Corp (AVXL)



Company website:  http://www.anavex.com/
 
 Nasdaq 
 
Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA
1-844-689-3939

 
CIK:  0001314052
 

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer.  The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.  Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.  The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial.  ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.

Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL

.
 
Management:   http://www.anavex.com/about-us/leadership/
 
Pipeline:  http://www.anavex.com/pipeline/

Patent Info: 
http://www.anavex.com/?s=patents

Clinical Trials:  https://clinicaltrials.gov/ct2/results?term=Anavex+Life+Sciences&Search=Search
 
Recent News:  http://finance.yahoo.com/q?s=avxl&ql=1
Company News Releases:  http://www.anavex.com/2015/?post_type=news
 
Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=anavex&owner=exclude&action=getcompany
 
Share Structure:  See SEC filings
 
Investor Relations:  ir@anavex.com

Marketing Details:  http://convention.bio.org/Printables/Anavex%20Life%20Sciences%20Corp..html

 



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
AVXL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXL News: Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference 11/25/2020 07:00:00 AM
AVXL News: Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Demen... 11/06/2020 10:45:00 AM
AVXL News: Current Report Filing (8-k) 10/15/2020 07:05:29 AM
AVXL News: Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-... 10/15/2020 07:00:10 AM
AVXL News: Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial 09/10/2020 07:00:10 AM
PostSubject
#285025  Sticky Note Compiled Due Diligence 09/29/19 & more ******** XenaLives 11/25/20 08:22:41 AM
#281223  Sticky Note A mixed bag presentation as expected. Doc328 11/06/20 02:05:55 PM
#281217  Sticky Note This write-up serves as an overview for Anavex's MayoMobile 11/06/20 01:51:51 PM
#276269  Sticky Note LOL. Why there is zero numerical data in KobeF 10/15/20 03:22:53 PM
#285244   8% more of the wt only subjects were blu_1 11/26/20 01:33:32 PM
#285243   Yes that is exactly how it should been Investor2014 11/26/20 01:29:49 PM
#285242   No conditions are "treatable" with Anavex 2-73. Some Investor2014 11/26/20 01:25:08 PM
#285241   There was no conspiracy - SP reacted appropriately Doc328 11/26/20 01:22:30 PM
#285240   Anavex corporate Presentation georgejjl 11/26/20 01:18:40 PM
#285239   Keeping things focused w/a risk averse regulatory body tredenwater2 11/26/20 01:15:36 PM
#285238   Pure BS is your prediction this will be Spudskie 11/26/20 01:07:52 PM
#285237   Statistically significant dose-dependent (p = 0.003) improvement of georgejjl 11/26/20 12:58:52 PM
#285236   I’m just going to keep my hopes positive Doc328 11/26/20 12:51:02 PM
#285235   End of Phase 2 meetings are common and Doc328 11/26/20 12:49:18 PM
#285234   Proof of Concept Controlled Phase 2 Clinical Trial georgejjl 11/26/20 12:21:37 PM
#285231   DISAPPOINTING PDD IS NOT A DISEASE OR CONDITION rayovacAAA 11/26/20 12:10:10 PM
#285225   If the FDA wants to step up and tradeherpete 11/26/20 11:22:32 AM
#285223   Diseases and conditions treatable with Anavex 2-73 georgejjl 11/26/20 11:13:19 AM
#285222   Nidan, Thanks for your response. tradeherpete 11/26/20 11:06:53 AM
#285221   Topline data U.S. Phase 2 RTT – Q4 2020 georgejjl 11/26/20 11:06:27 AM
#285220   HAPPY THANKSGIVING DAY georgejjl 11/26/20 10:47:05 AM
#285218   Still like my idea of going Black Market in McMagyar 11/26/20 10:33:54 AM
#285217   tradeherpeteHow long should it take for Dr. Missling nidan7500 11/26/20 10:24:35 AM
#285216   Yes.. Dr K .. Will be making his case McMagyar 11/26/20 10:20:12 AM
#285213   PK data is objective and not meaningless, but Investor2014 11/26/20 09:59:58 AM
#285211   The difficulty with Alzheimers Is since the death McMagyar 11/26/20 09:32:43 AM
#285210   How long should it take for Dr. Missling tradeherpete 11/26/20 09:10:47 AM
#285208   IF THE DATA IS MEANINGLESS, WHY DID AVXL rayovacAAA 11/26/20 09:00:02 AM
#285205   Yes, the wtS1 is apparently our best predictive frrol 11/26/20 08:27:42 AM
#285204   $AVXL 80% Technical "BUY" Signal Golden_Cross 11/26/20 08:23:28 AM
#285202   "I'm hoping it is!"--I doubt the co. would plexrec 11/26/20 07:50:41 AM
#285201   Hint: What does "% patients in top interval" Investor2014 11/26/20 07:40:21 AM
#285200   Safety issues and efficacy can terminate trials, but frrol 11/26/20 07:04:07 AM
#285199   Not 8% "higher" (though at least you know frrol 11/26/20 06:54:29 AM
#285198   Anavex will not be saying that or releasing Investor2014 11/26/20 06:46:12 AM
#285197   Has Anavex said if will be giving any blu_1 11/26/20 06:34:50 AM
#285196   Is this the answer you're looking for? baltimorebullet 11/26/20 04:21:42 AM
#285195   The CRO has the ability to cut short boi568 11/26/20 03:06:03 AM
#285193   You may have noticed, I am no cabalist. boi568 11/26/20 02:57:34 AM
#285192   You’re sane, and are making a very cogent JWC3 11/26/20 01:53:48 AM
#285190   That's because open label data on 3 patients Investor2014 11/26/20 01:43:58 AM
#285189   Yes no new data or information released, still Investor2014 11/26/20 01:42:15 AM
#285188   All real investment groups have used clairvoyance for decades. Investor2014 11/26/20 01:26:21 AM
#285187   Right before that was a long attack. Investor2014 11/26/20 01:22:15 AM
#285186   hello..my name is sanity.. McMagyar 11/26/20 01:13:37 AM
#285185   Oh geez, so what's your issue w/slide 17? blu_1 11/26/20 12:10:01 AM
#285184   Unfortunately we have a rigged system in this bb8675309 11/25/20 11:38:07 PM
#285180   Pure bullshit basparks79 11/25/20 11:14:11 PM
#285178   Bullshit! basparks79 11/25/20 11:07:48 PM
#285176   Based on the only comparative slide for that frrol 11/25/20 07:01:29 PM
#285175   Thanks treden Xlendi 11/25/20 06:37:18 PM
#285174   Lol BTW thank you Xlendi 11/25/20 06:34:29 PM
#285171   A few seconds after it reaches $1249/share. raja48185 11/25/20 06:07:17 PM
#285170   Same to you sir ! and hoping AVXL raja48185 11/25/20 06:04:15 PM
PostSubject
Consent Preferences